Pluvicto®▼ (lutetium [¹⁷⁷Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.¹

Locametz®▼(gozetotide) is for diagnostic use only. Locametz, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer.²

 

Clinical Trials

VISION was an international, prospective, randomised, open-label, multicentre, Phase III study (N=831) to assess the efficacy and safety profile of Pluvicto plus investigator-chosen best standard of care (BSoC) in the investigational arm, versus BSoC in the control arm. Patients with PSMA positron emission tomography (PET)-scan positive mCRPC, and progression after prior taxane and androgen receptor pathway inhibitors, were randomised in a 2:1 ratio in favour of the investigational arm. The alternate primary endpoints were radiographic progression-free survival (rPFS) and overall survival (OS).³

View the study design for VISION below.